Publicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (25)

2023

  1. Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)

    Nature Reviews Cardiology

  2. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT

    International Journal of Cardiology, Vol. 383, pp. 24-32

  3. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions

    Journal of the American College of Cardiology, Vol. 82, Núm. 8, pp. 687-700

  4. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial

    American Journal of Cardiology, Vol. 208, pp. 16-24

  5. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524

  6. Optical coherence tomography and coronary revascularization: from indication to procedural optimization

    Trends in Cardiovascular Medicine, Vol. 33, Núm. 2, pp. 92-106

  7. The year in cardiovascular medicine 2021: interventional cardiology

    Cardiologia Hungarica, Vol. 53, Núm. 1, pp. 5-14

  8. Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 328-336

2022

  1. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 19, pp. 1948-1960

  2. Optical coherence tomography in coronary atherosclerosis assessment and intervention

    Nature Reviews Cardiology, Vol. 19, Núm. 10, pp. 684-703

  3. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 17, Núm. 16, pp. 1330-1339

  4. The year in cardiovascular medicine 2021: interventional cardiology

    European heart journal, Vol. 43, Núm. 5, pp. 377-386

  5. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 3, pp. 282-293

  6. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 7, pp. 707-716

  7. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 11, pp. e897-e909

2021

  1. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial

    The Lancet, Vol. 398, Núm. 10317, pp. 2149-2159

  2. Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 78, Núm. 8, pp. 840-853

  3. Sex Differences among Patients with High Risk Receiving Ticagrelor with or without Aspirin after Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial

    JAMA Cardiology, Vol. 6, Núm. 9, pp. 1032-1041

  4. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis

    JACC: Cardiovascular Interventions, Vol. 14, Núm. 4, pp. 444-456

  5. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR

    European Heart Journal, Vol. 42, Núm. 45, pp. 4624-4634